Association of tumor mutational burden with genomic alterations in Chinese urothelial carcinoma-Reference-Cited by-同舟云学术

Association of tumor mutational burden with genomic alterations in Chinese urothelial carcinoma

Published:2021-11-02 Issue: Volume: Page:
ISSN:0899-1987
Container-title:Molecular Carcinogenesis
language:en
Short-container-title:Molecular Carcinogenesis

Author:

Chen Xusheng¹,Ou Zhenyu²,Wang Lei³,Zhang Zhenting¹,Fan Xiaodong⁴,Liu Huanhuan⁵,Wang Wenping⁵,Zhang Yanrui⁵,Zhu Jun⁶⁷⁸,Liang Xiayuan⁵,Lou Feng⁵,Cao Shanbo⁵,Yao Ye⁹,Wang Huina⁵,Yao Xin¹

Affiliation:

1. Department of Geniturinary Oncology Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, Tianjin's Clinical Research Center for Cancer Tianjin China

2. Department of Urology Xiangya Hospital, Central South University Changsha Hunan China

3. Department of Oncology The Second Hospital of Tianjin Medical University Tianjin China

4. Department of Urology Ningbo Urology & Nephrology Hospital, Ningbo Zhejiang China

5. Acornmed Biotechnology Co., Ltd. Beijing PR China

6. Department of Genomics and Multiscale Biology Icahn School of Medicine at Mount Sinai New York New York USA

7. Department of Genomic Sciences Icahn School of Medicine at Mount Sinai New York New York USA

8. Department of Medicine, Division of Hematology Oncology Icahn School of Medicine at Mount Sinai New York New York USA

9. Department of College of Art and Science Ohio State University Columbus Ohio USA

Publisher

Wiley

Subject

Cancer Research,Molecular Biology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/mc.23368

Reference35 articles.

1. Urothelial carcinoma detection based on copy number profiles of urinary cell‐free DNA by shallow whole‐genome sequencing;Guangzhe G;Clin Chem,2019

2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

3. Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma

4. Clonal evolution of chemotherapy-resistant urothelial carcinoma

5. NCCN Guidelines Version 3.2020 Bladder Cancer;Flaig TW;NCCN,2020